U.S. Markets close in 59 mins
  • S&P 500

    4,580.13
    +13.13 (+0.29%)
     
  • Dow 30

    34,479.90
    -3.82 (-0.01%)
     
  • Nasdaq

    15,491.54
    -46.15 (-0.30%)
     
  • Russell 2000

    2,188.99
    -9.92 (-0.45%)
     
  • Crude Oil

    65.98
    -0.20 (-0.30%)
     
  • Gold

    1,782.40
    +5.90 (+0.33%)
     
  • Silver

    22.26
    -0.50 (-2.22%)
     
  • EUR/USD

    1.1321
    -0.0018 (-0.1585%)
     
  • 10-Yr Bond

    1.4490
    +0.0060 (+0.42%)
     
  • Vix

    26.31
    -0.88 (-3.24%)
     
  • GBP/USD

    1.3280
    -0.0021 (-0.1594%)
     
  • USD/JPY

    112.8000
    -0.3800 (-0.3357%)
     
  • BTC-USD

    57,460.32
    -170.31 (-0.30%)
     
  • CMC Crypto 200

    1,468.50
    -0.58 (-0.04%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Concert Pharma Sells VX-561-Related Milestones To Vertex For $32M

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Concert Pharmaceuticals Inc (NASDAQ: CNCE) has sold potential future milestones relating to VX-561 (deutivacaftor) under the 2017 asset purchase agreement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $32 million.

  • "This transaction provided an opportunity to secure non-dilutive capital and strengthens our balance sheet as we continue to advance CTP-543, our lead asset for alopecia areata, through its Phase 3 program," stated Roger Tung, President and CEO of Concert Pharmaceuticals.

  • "By receiving these proceeds, we now expect our cash, cash equivalents, and investments to fund the Company into the second quarter of 2022."

  • Under the asset purchase agreement, Vertex acquired worldwide development and commercialization rights to VX-561 for cystic fibrosis.

  • In 2017, Concert received a one-time cash payment of $160 million on closing the asset purchase, with the potential for $90 million in future milestones.

  • Following receipt of the $32 million, no further milestone obligations remain.

  • Price Action: CNCE shares closed at $4.03, and VRTX shares closed at $216.35 on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.